Skip to main content
Monday, November 16, 2026Nov 16

Health care M&A leads global deal surge

In this Thursday, Feb. 28, 2013 photo, Merck scientist Janet Lineberger conducts research to discover new HIV drugs in West Point, Pa. The health care industry has announced about $438 billion worth of mergers and acquisitions worldwide so far, about 14 percent of the $3.2 trillion total for all industries, according to data provider Dealogic. Merck & Co. agreed in June to pay nearly $4 billion for Idenix Pharmaceuticals Inc. to combine that company's hepatitis C medicines with its own. (AP Photo/Matt Rourke)
In this Thursday, Feb. 28, 2013 photo, Merck scientist Janet Lineberger conducts research to discover new HIV drugs in West Point, Pa. The health care industry has announced about $438 billion worth of mergers and acquisitions worldwide so far, about 14 percent of the $3.2 trillion total for all industries, according to data provider Dealogic. Merck & Co. agreed in June to pay nearly $4 billion for Idenix Pharmaceuticals Inc. to combine that company's hepatitis C medicines with its own. (AP Photo/Matt Rourke)

In a big year for deal making, the health care industry is a standout.

Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and low interest rates are also fueling the mergers and acquisitions.

It’s all combining to make 2014 the most active year for health care deals in at least two decades. The industry has announced about $438 billion worth of mergers and acquisitions worldwide so far, about 14 percent of the $3.2 trillion total for all industries, according to data provider Dealogic. Overall, M&A is on track for its best year since 2007, the year before the financial crisis intensified.

“Health care has been a sleepy niche of M&A until recently, but the giant has been awakened,” says Ken Menges, a senior partner handling M&A at law firm Akin Gump in New York.

To a large extent, the deals are being driven by “cost pressure on the entire health care system,” as insurers and government health plans increasingly hold down or even reduce reimbursements to drug, device and service providers, says Ashtyn Evans, pharmaceutical and biotech analyst with investment firm Edward Jones in St. Louis, Missouri.